PPA
AKBA icon

Parametric Portfolio Associates’s Akebia Therapeutics AKBA Stock Holding History

Parametric Portfolio Associates’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$26K Sell
36,219
-23,045
-39% -$49.3K ﹤0.01% 3655
2021
Q4 		$134K Sell
59,264
-30,193
-34% -$82.3K ﹤0.01% 3507
2021
Q3 		$258K Sell
89,457
-37,012
-29% -$106K ﹤0.01% 3356
2021
Q2 		$479K Sell
126,469
-68,028
-35% -$229K ﹤0.01% 3103
2021
Q1 		$658K Sell
194,497
-64,643
-25% -$233K ﹤0.01% 3358
2020
Q4 		$726K Buy
259,140
+199,283
+333% +$582K ﹤0.01% 3202
2020
Q3 		$150K Sell
59,857
-124,180
-67% -$1.09M ﹤0.01% 3727
2020
Q2 		$2.5M Buy
184,037
+83,340
+83% +$862K ﹤0.01% 2364
2020
Q1 		$763K Buy
100,697
+32,414
+47% +$252K ﹤0.01% 2950
2019
Q4 		$432K Sell
68,283
-145,437
-68% -$691K ﹤0.01% 3422
2019
Q3 		$838K Buy
213,720
+14,204
+7% +$60.9K ﹤0.01% 3111
2019
Q2 		$966K Buy
199,516
+64,835
+48% +$369K ﹤0.01% 3065
2019
Q1 		$1.1M Sell
134,681
-114,788
-46% -$788K ﹤0.01% 2981
2018
Q4 		$1.38M Buy
249,469
+227,364
+1,029% +$1.78M ﹤0.01% 2812
2018
Q3 		$195K Sell
22,105
-885
-4% -$7.92K ﹤0.01% 3769
2018
Q2 		$229K Buy
22,990
+5,626
+32% +$56.3K ﹤0.01% 3655
2018
Q1 		$165K Sell
17,364
-78,100
-82% -$1.09M ﹤0.01% 3797
2017
Q4 		$1.42M Sell
95,464
-9,734
-9% -$161K ﹤0.01% 2823
2017
Q3 		$2.07M Buy
105,198
+31,074
+42% +$478K ﹤0.01% 2565
2017
Q2 		$1.06M Buy
+74,124
New +$940K ﹤0.01% 2951
2016
Q4 		– Sell
-10,555
Closed -$96K – 3769
2016
Q3 		$96K Buy
+10,555
New +$89.7K ﹤0.01% 3687
2016
Q1 		– Sell
-23,807
Closed -$308K – 3968
2015
Q4 		$308K Buy
23,807
+12,731
+115% +$130K ﹤0.01% 3551
2015
Q3 		$107K Sell
11,076
-666
-6% -$6.11K ﹤0.01% 3182
2015
Q2 		$121K Buy
+11,742
New +$100K ﹤0.01% 3850

Other funds holding AKBA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
OCM
Orchard Capital Management Chicago, Illinois $103M AUM 65.87% 1-Year Est. Return

Parametric Portfolio Associates's AKBA Position: Q1 2022 in Review

Parametric Portfolio Associates reduced its Akebia Therapeutics (AKBA) stake by 39% in Q1 2022, selling an estimated $49.3K and leaving 36,219 shares worth $26K. The position accounts for ﹤0.01% of the portfolio, ranked #3655.

Parametric Portfolio Associates first reported a position in AKBA in Q2 2015 and has held it in 24 quarters since. The position peaked at $2.5M in Q2 2020. 124 funds tracked by Wall St. Rank hold AKBA as of Q1 2022.

  • Parametric Portfolio Associates held 36,219 shares of Akebia Therapeutics worth $26K as of Q1 2022.
  • Parametric Portfolio Associates sold 23,045 Akebia Therapeutics shares in Q1 2022, an estimated $49.3K.
  • Akebia Therapeutics made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #3655 holding.
  • Parametric Portfolio Associates first reported a position in Akebia Therapeutics in Q2 2015 and has held it in 24 quarters since.
  • Parametric Portfolio Associates's Akebia Therapeutics position peaked at $2.5M in Q2 2020.
  • 124 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.